Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study

被引：0
|
作者：
Alvarez, R. [1 ]
Carcereny, E. [2 ,3 ]
Padilla, A. [4 ]
Rodriguez Garcia, J. M. [5 ]
Cordoba, J. F. [6 ]
Esteban, E. [7 ]
Aguado, C. [8 ]
Garde, J. [9 ]
Moreno Vega, A. [10 ]
Avila Andrade, C. [11 ]
Sereno, M. [12 ]
Sanchez-Hernandez, A. [13 ]
Lopez-Brea, M. [14 ]
Massuti, B. [15 ]
Marti Blanco, C. [16 ]
Campayo, M. [17 ]
Arnaiz, P. [18 ]
Perez Parente, D. [18 ]
Fajardo, C. A. [18 ]
Ramos, I. [19 ]
机构：
[1] Hosp Gregorio Maranon, Madrid, Spain
[2] Catalan Inst Oncol ICO Badalona, Germans Trias & Pujol Res Inst IGTP, Dept Med Oncol, Badalona, Spain
[3] Badalona Appl Res Grp Oncol B ARGO, Germans Trias & Pujol Res Inst IGTP, Badalona, Spain
[4] Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain
[5] Hosp San Pedro Alcantara, Caceres, Spain
[6] Hosp Arnau Vilanova, Lleida, Spain
[7] Hosp Univ Cent Asturias, Oviedo, Spain
[8] Hosp Clin San Carlos, Madrid, Spain
[9] Hosp Arnau Vilanova, Valencia, Spain
[10] Hosp Univ Reina Sofia, Cordoba, Spain
[11] Hosp Lluis Alcanyis Xativa, Valencia, Spain
[12] Hosp Infanta Sofia, Madrid, Spain
[13] Consorci Hosp Prov Castello, Castellon De La Plana, Spain
[14] Hosp Univ Marques Valdecilla, Santander, Spain
[15] Hosp Gen Alicante, Alicante, Spain
[16] Hosp Univ Sant Joan Reus, Reus, Spain
[17] Hosp Univ Mutua Terrassa, Terrassa, Spain
[18] Roche Farma SA, Madrid, Spain
[19] Hosp Univ Virgen Victoria, Malaga, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Real-World Data; NSCLC; atezolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.03-13
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [21] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
    Yung-Hung Luo
    Han Liu
    Jason A. Wampfler
    Henry D. Tazelaar
    Yalun Li
    Tobias Peikert
    Dan Liu
    Konstantinos Leventakos
    Yuh-Min Chen
    Yanan Yang
    Shih-Hwa Chiou
    Ping Yang
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2099 - 2114
  • [22] Sugemalimab in locally advanced and advanced Chinese NSCLC: A real-world retrospective study
    Liu, Jiayu
    Wang, Yan
    Wang, Qi
    Yang, Ke
    Xie, Tongji
    Sun, Dantong
    Wu, Lige
    Li Junling
    Xing, Puyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Pembrolizumab for Previously Treated, PD-L1-Expressing Advanced NSCLC: Real-World Time on Treatment and Overall Survival
    Velcheti, V.
    Chandwani, S.
    Chen, X.
    Piperdi, B.
    Burke, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S882 - S882
  • [24] Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Piperdi, Bilal
    Burke, Thomas
    CLINICAL LUNG CANCER, 2020, 21 (05) : E445 - E455
  • [25] Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy
    Haggstrom, D.
    Mhatre, S. K.
    Chen, F.
    Gao, R.
    Carroll, C.
    Patel, R.
    Park, J.
    Descoteaux, A.
    Stokes, M.
    Daniel, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S409 - S409
  • [26] Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan
    Wu, Shang -Gin
    Chiang, Chi-Lu
    Wang, Chin -Chou
    Hung, Jen-Yu
    Hsia, Te-Chun
    Kuo, Chih-Hsi
    Shih, Jin-Yuan
    JOURNAL OF CANCER, 2022, 13 (09): : 2922 - 2932
  • [27] Real-world insights into patients (pts) with advanced NSCLC and MET alterations
    Bittoni, M.
    Yang, J. C-H.
    Shih, J-Y.
    Peled, N.
    Smit, E.
    Camidge, R.
    Carbone, D.
    Oksen, D.
    Boutmy, E.
    Johne, A.
    Paik, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1398 - S1399
  • [28] Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
    Zhang, Song
    Wang, Xin
    Gu, Hao
    Liu, Jun-Qi
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1715 - 1727
  • [29] Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis
    Heffernan, Kiera
    Sen Nikitas, Fulya
    Shukla, Urmi
    Camejo, Helen Starkie
    Knott, Craig
    GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 317 - 325
  • [30] Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study
    Mouritzen, Mette T.
    Junker, Karen F.
    Carus, Andreas
    Ladekarl, Morten
    Meldgaard, Peter
    Nielsen, Anders W. M.
    Livbjerg, Anna
    Larsen, Jacob W.
    Skuladottir, Halla
    Kristiansen, Charlotte
    Wedervang, Kim
    Schytte, Tine
    Hansen, Karin H.
    Ostby, Anne-Cathrine
    Frank, Malene S.
    Lauritsen, Jakob
    Sorensen, Jens B.
    Langer, Seppo W.
    Persson, Gitte F.
    Andersen, Jon L.
    Homann, Pernille H.
    Kristensen, Emilie B.
    Drivsholm, Lars B.
    Bogsted, Martin
    Christensen, Heidi S.
    Pohl, Mette
    Bjornhart, Birgitte
    ACTA ONCOLOGICA, 2022, 61 (04) : 409 - 416
12345